NorthWest Biotherapeutics Inc (NWBO)

[Gus1212]

Is this a joke? ---- OMG ---- Let's Roll and Save Some Lives
1.7 Months ? Take Two Aspirin and call me in the morning ----
I must be missing something ...... Help Me Out


The FDA-mandated EF-19 post-approval registry trial studied Optune as a monotherapy for the treatment of recurrent GBM in 192 patients compared to the 117 recurrent GBM patients who received best standard of care chemotherapy in Novocure's EF-11 registration trial. Optune as monotherapy reduced the risk of death with fewer adverse events compared to best standard of care chemotherapy. For patients who received at least one course of therapy, Optune prolonged survival by a median 1.7 months. No new safety signals were noted. The EF-19 data confirm the effectiveness and safety of Optune as monotherapy and further strengthen Optune's clinical profile in recurrent GBM.


NovoCure announces presentation of EF-19 post-approval registry trial data studying optune as a monotherapy for the treatment of recurrent GBM at the American Association for Cancer Research 2020 Virtual Annual Meeting  NVCR